Extending survival with chemotherapy in metastatic breast cancer.
about
Single agent versus combination chemotherapy for metastatic breast cancerCurcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast CancerTargeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerTaxanes in the elderly patient with metastatic breast cancerEffects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumorsPG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma modelCausal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving SurgeryImplications of Hypoxia in Breast Cancer Metastasis to BoneEpithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3?Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialDifferential Proteome Analysis Identifies TGF-β-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer ModelA meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.Regulation of mitosis and taxane response by Daxx and Rassf1.Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunctionFeasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.Measures of outcome in metastatic breast cancer: insights from a real-world scenarioTreatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States.Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.Downregulation of ATG5-dependent macroautophagy by chaperone-mediated autophagy promotes breast cancer cell metastasis.Considerations for payers in managing hormone receptor-positive advanced breast cancer.14-3-3τ promotes breast cancer invasion and metastasis by inhibiting RhoGDIαChemotherapy resistance in metastatic breast cancer: the evolving role of ixabepiloneNox4-dependent ROS modulation by amino endoperoxides to induce apoptosis in cancer cellsOverall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosisNasal cavity metastasis of breast cancer: a case report and review of the literature.Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA.CTC enumeration and characterization: moving toward personalized medicine.HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancerHigher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patientsA Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel In Vivo Metastasis Model.Multivariate frailty models for two types of recurrent events with a dependent terminal event: application to breast cancer data.Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.Nucleostemin expression in invasive breast cancer.Predicting survival of de novo metastatic breast cancer in Asian women: systematic review and validation study.Downregulation of Ras association domain family member 6 (RASSF6) underlies the treatment resistance of highly metastatic nasopharyngeal carcinoma cells.
P2860
Q24241459-A0880BA5-8230-4C60-AD9D-D4979D8C1694Q26744566-699C3D64-0257-4DC3-A14D-4E9435655DBDQ26745420-778EADF1-CF2D-4C31-883C-C7A377B959FEQ26770482-DECA4145-0738-4CAB-8780-6D23FCAFBBAEQ26785458-624CE229-BFA5-46AA-8CB2-6E41071C1F21Q26799046-0D8698FD-2476-415E-86F3-B02B4068DEA8Q27327191-03B0C9DB-7240-4896-BCF2-45EE8F36B02AQ28069804-9C00F129-899D-4FCB-98A9-12526AA3F21FQ28077444-787A81B3-8924-437E-A087-8FCF81331A14Q28087055-4FA9A48E-F39D-47D6-A91E-E125BA3FF005Q28267134-F3F4092E-2959-42D8-9C53-496885F89625Q28534786-40A2B018-AAE6-49EF-8138-BB78B56DCCC7Q28547327-A9BB3028-D114-4E8A-8C40-19F38284A658Q30390845-817FC9C8-9BC6-4C44-93F6-B056AF726963Q30574064-98545022-D856-4C40-A487-BD561FD7D6DAQ30835794-6492E7D8-013B-48AB-864D-C9C0AFBA303CQ33408664-B86C7FB8-95C2-48EE-9D7D-A07747B7925CQ33421995-85FD9FF5-44C7-4DD6-97EF-32A10A74FA1FQ33584160-D5C53C10-5BD6-45EF-AC00-1BF8E2C6FA67Q33699649-E3AC7558-1E79-4563-8C11-F58545725311Q33760059-2723E2CD-C3EA-4C0F-9BCD-E567547E394EQ33762423-C1CABB0D-D401-49B1-BB8F-016647F1E3E6Q33881209-B4552208-4D92-405A-B425-89A84D5CBDF7Q33895422-8B14B197-013E-47B8-A5CA-B5E5E7C8B418Q33899871-88C0F134-A0C0-4BC1-AAA4-D87FEBE608A3Q34274930-1E9AD610-FC65-48EC-868E-55C5CE78BEEDQ34334633-9D67F91E-B96F-4260-83D4-6C3252F00D01Q34478105-4859EDEB-4BC6-47EE-BA40-F4E033348D2BQ34501871-13CCB023-9267-4DAA-AC43-3CBD3BDF9A4FQ34519307-52AF0539-8C11-4D8A-AA00-43A5DA0A62A3Q34577724-D0373B1E-2C38-4911-BE1D-59802250D839Q34614133-A4729202-36D7-47F1-97B7-FAA1D36D7794Q34713757-6EDA8976-B94F-432A-9220-3347BD09FDA8Q34761601-DDB7818D-88D9-4931-96C1-EB26F076AB61Q34796819-DA144A75-D774-4A51-B3DE-59CB6D5AE0B6Q34912479-C049E41C-A694-424D-9BA9-BBB66812BB5FQ34983601-363CE572-B809-4834-AD6A-D52A1AC95D74Q35125899-FC0DF696-6EBA-48A6-8B94-16A4D5F00D21Q35138699-248F1F03-4067-4080-A1B4-4C3D10EF8788Q35207555-057E3216-4991-400F-B75E-2C44F8A47E1F
P2860
Extending survival with chemotherapy in metastatic breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Extending survival with chemotherapy in metastatic breast cancer.
@ast
Extending survival with chemotherapy in metastatic breast cancer.
@en
type
label
Extending survival with chemotherapy in metastatic breast cancer.
@ast
Extending survival with chemotherapy in metastatic breast cancer.
@en
prefLabel
Extending survival with chemotherapy in metastatic breast cancer.
@ast
Extending survival with chemotherapy in metastatic breast cancer.
@en
P1433
P1476
Extending survival with chemotherapy in metastatic breast cancer.
@en
P2093
Joyce O'Shaughnessy
P356
10.1634/THEONCOLOGIST.10-90003-20
P478
10 Suppl 3
P577
2005-01-01T00:00:00Z